in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Valeant Pharmaceuticals, Baxter and Achaogen.
Valeant Pharmaceuticals International has extended the contract of its CEO Michael Pearson. The new agreement will see Pearson continue as CEO until February 2017 and also succeed Robert Ingram as chairman of the board of directors. Ingram remains on the Valeant board.
The board of directors at Baxter has elected James Saccaro as treasurer and a corporate officer. Saccaro succeeds Robert Hombach, who was named chief financial officer in 2010, as treasurer.
Kenneth Hillan has been appointed chief medical officer at Achaogen. Hillan worked at Genentech for the past 16 years, ending his time at the biotech as senior vice president and head of product development.
Clariant Masterbatches has given Gunther Luebke responsibility for the ISO 13485 quality system and oversight of specific regulatory requirements. Earlier in his career Luebke was part of the Clariant team within the Masterbatch business unit on REACH.
Michael Meyers has joined the board of directors at Aeterna Zentaris. Meyers co-founded Arcoda Capital Management in 2007 and serves as its CEO and chief investment officer.
Huifeng Bio-Pharmaceutical Technology has named Amy Xue as senior vice president (SVP) of finance. Xue founded Farolfi & Company in 2010 and previously worked at Acquavella, Chiarelli, Shuster, Berkower & Co.
Ashley Bush has joined the scientific advisory board at Adeona Pharmaceuticals. Bush is a National Health and Medical Research Council Australia Fellow and head of the Oxidation Disorders Laboratory for the Mental Health Research Institute, University of Melbourne.